Loss of CD169 + Subcapsular Macrophages during Metastatic Spread of Head and Neck Squamous Cell Carcinoma

Abstract

Objective

The purpose of this study is to assess CD169 expression in metastatic and nearby tumor-free lymph nodes of patients with head and neck squamous cell carcinoma (SCC).

Study Design

Retrospective analysis based on immunohistochemistry.

Setting

Tertiary care center.

Subjects and Methods

The abundance of CD169⁺ cells in the subcapsular sinuses (SCSs) of lymph nodes was assessed immunohistochemically in paraffin-embedded tissue samples derived from 22 patients with oral cavity and oropharyngeal SCC.

Results

SCSs of lymph nodes harboring metastatic SCC contained significantly fewer CD169⁺ macrophages (106.5 ± 113.6 cells/mm²) compared to nearby tumor-free lymph nodes (321.3 ± 173.4 cells/mm², P < .001). This observation extended to 21 of the 22 cases investigated. In addition, 6 patients who later developed recurrent disease contained lower numbers of CD169⁺ cells (268.6 ± 169.5 cells/mm²) in nearby tumor-free lymph nodes compared to 341.0 ± 176.1 cells/mm² in those who remained disease free (P = .399). Human papillomavirus (HPV)–positive patients (n = 4) had a 6-fold lower number of CD169⁺ cells in metastatic nodes (61.2 ± 85.5 cells/mm²) compared to nearby tumor-free lymph nodes (369.5 ± 175.5 cells/mm², P = .028). In comparison, HPV-negative patients had only a 3-fold reduction (116.6 ± 118.5 cells/mm² vs 310.6 ± 176.2 cells/mm², P < .001).

Conclusion

Metastatic spread of SCC to regional lymph nodes is associated with lower abundance of CD169⁺ macrophages in the SCSs of draining lymph nodes. These results set the stage for an in-depth investigation into the mechanism(s) by which metastatic SCC controls CD169⁺ macrophage abundance and its significance as it relates to prognosis and treatment response.

Keywords

head and neck cancer metastasis human papillomavirus immunotherapy

Get full access to this article

View all access options for this article.

References

Marur

Forastiere

AA.

Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489-501.

Siegel

Miller

Jemal

Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.

Bauman

Cohen

Ferris

et al . Immunotherapy of head and neck cancer: emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017;123:1259-1271.

Burnet

FM.

The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1-27.

Schreiber

Old

Smyth

MJ.

Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565-1570.

Montero

Palmer

et al . Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma. Cancer. 2014;120:214-221.

Coskun

Medina

Robbins

et al . Current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma. Head Neck. 2015;37:915-926.

Kumagai

Hamada

Gotoh

et al . Evidence for the changes of antitumor immune response during lymph node metastasis in head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:341-350.

Wehrhan

Buttner-Herold

Hyckel

et al . Increased malignancy of oral squamous cell carcinomas (OSCC) is associated with macrophage polarization in regional lymph nodes—an immunohistochemical study. BMC Cancer. 2014;14:522.

10.

Goncalves

Costa

Arantes

de Cassia Goncalves Alencar

Silva

Batista

AC.

Immune response in cervical lymph nodes from patients with primary oral squamous cell carcinoma. J Oral Pathol Med. 2013;42:535-540.

11.

Curry

Tassone

Gill

et al . Tumor metabolism in the microenvironment of nodal metastasis in oral squamous cell carcinoma. Otolaryngol Head Neck Surg. 2017;157:798-807.

12.

Pucci

Garris

Lai

et al . SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 2016;352:242-246.

13.

Schaale

Brandenburg

Kispert

Leitges

Ehlers

Reiling

Wnt6 is expressed in granulomatous lesions of Mycobacterium tuberculosis–infected mice and is involved in macrophage differentiation and proliferation. J Immunol. 2013;191:5182-5195.

14.

Simon

MC.

PU.1 and hematopoiesis: lessons learned from gene targeting experiments. Semin Immunol. 1998;10:111-118.

15.

Saito

Ohnishi

Miyashita

et al . Prognostic significance of CD169+ lymph node sinus macrophages in patients with malignant melanoma. Cancer Immunol Res. 2015;3:1356-1363.

16.

Ohnishi

Yamaguchi

Erdenebaatar

et al . Prognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinoma. Cancer Sci. 2016;107:846-852.

17.

Shiota

Miyasato

Ohnishi

et al . The clinical significance of CD169-positive lymph node macrophage in patients with breast cancer. PLoS One. 2016;11(11):e0166680.

18.

Stromvall

Sundkvist

Ljungberg

Halin Bergstrom

Bergh

Reduced number of CD169(+) macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients. Prostate. 2017;77:1468-1477.

19.

Edge

Compton

CC.

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.

20.

Asano

Nabeyama

Miyake

et al . CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011;34:85-95.

21.

Ang

Harris

Wheeler

et al . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.

22.

Spector

Gallagher

Bellile

et al . Patterns of nodal metastasis and prognosis in human papillomavirus–positive oropharyngeal squamous cell carcinoma. Head Neck. 2014;36:1233-1240.

23.

Mendelsohn

Lai

Shintaku

et al . Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope. 2010;120:1788-1794.